Characteristics of arterial hypertension clinical course in patients with obesity and anxiety-depressive disorders

Cover Page

Cite item

Full Text

Abstract

This article covers an important subject – clinical course of arterial hypertension in patients with metabolic abnormalities with obesity and anxiety-depressive disorders. Relevance of this topic is defined with high incidence of each aforementioned conditions and their influence on quality of life and social functioning of patients. Review of literature covers subjects of comorbidity and multimorbidity. Relevant data are presented which are focusing on complex management of arterial hypertension co-existing with obesity and anxiety-depressive disorders.

About the authors

Yuri A. Vasyuk

Yevdokimov Moscow State University of Medicine and Dentistry

Author for correspondence.
Email: yvasyuk@yandex.ru
ORCID iD: 0000-0003-2913-9797

д.м.н., проф., зав. каф. госпитальной терапии №1 ФГБОУ ВО «МГМСУ им. А.И. Евдокимова»

Russian Federation, 20/1, Delegatskaya street, Moscow, 127473

Tatiana V. Dovzhenko

Serbsky State Scientific Center for Social and Forensic Psychiatry

Email: yvasyuk@yandex.ru
ORCID iD: 0000-0002-5456-2573

д.м.н., проф., гл. науч. сотр. лаб. психологического консультирования и психотерапии ФГБУ «НМИЦ ПН им. В.П. Сербского»

Russian Federation, 23, Kropotkin lane, Moscow, 119034

Tatiana I. Dubrovskaya

Yevdokimov Moscow State University of Medicine and Dentistry

Email: yvasyuk@yandex.ru
ORCID iD: 0000-0003-0044-6056

аспирант каф. госпитальной терапии №1 ФГБОУ ВО «МГМСУ им. А.И. Евдокимова»

Russian Federation, 20/1, Delegatskaya street, Moscow, 127473

Elena A. Nesterova

Yevdokimov Moscow State University of Medicine and Dentistry

Email: yvasyuk@yandex.ru
ORCID iD: 0000-0002-1808-6127

к.м.н., доц. каф. клинической функциональной диагностики ФГБОУ ВО «МГМСУ им. А.И. Евдокимова»

Russian Federation, 20/1, Delegatskaya street, Moscow, 127473

Elena Y. Shupenina

Yevdokimov Moscow State University of Medicine and Dentistry

Email: yvasyuk@yandex.ru
ORCID iD: 0000-0001-6188-4610

к.м.н., доц. каф. клинической функциональной диагностики ФГБОУ ВО «МГМСУ им. А.И. Евдокимова»

Russian Federation, 20/1, Delegatskaya street, Moscow, 127473

References

  1. Mills KT, Bundy JD, Kelly TN, et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 2016;134(6):441-50. doi: 10.1161/CIRCULATIONAHA.115.018912
  2. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for themanagement of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. doi: 10.1093/eurheartj/ehy339
  3. Чесникова А.И., Батюшин М.М., Терентьев В.П. Артериальная гипертензия и коморбидность: современное состояние проблемы. Артериальная гипертензия. 2016;22(5):433-40 [Chesnikova AI, Batyushin MM, Terent’ev VP. Arterial hypertension and comorbidity: current state of the problem. Arterial’naya gipertenziya. 2016;22(5):433-40 (In Russ.)]. doi: 10.18705/1607-419Х-2016-22-5-432-440
  4. Abad-Díez JM, Calderón-Larrañaga A, Poncel-Falcó A, et al. Age and gender differences in the prevalence and patterns of multimorbidity in the older population. BMC Geriatr. 2014;14:75. doi: 10.1186/1471-2318-14-75
  5. Noh J, Kim HC, Shin A, et al. Prevalence of comorbidity among people with hypertension: The Korea national health and nutrition examination survey 2007–2013. Korean Circ J. 2016;46(5):672-80. doi: 10.4070/kcj.2016.46.5.672
  6. Hall JE, Do Carmo JM, Da Silva AA, Wang Z, Hall ME. Obesity-Induced Hypertension: Interaction of Neurohumoral and Renal Mechanisms. Circ Res. 2015;116(6):991-1006. doi: 10.1161/CIRCRESAHA. 116.305697
  7. WHO. Obesity and overweight. Available at: https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight. Accessed: 28.05.2019.
  8. WHO. Depression. Available at: https://www.who.int/news-room/fact-sheets/detail/depression. Accessed: 25.05.2019.
  9. Мазо Г.Э., Кибитов А.О. Механизмы формирования коморбидности депрессии и ожирения. Обозрение психиатрии и мед. психологии им. В.М. Бехтерева. 2018;1:65-78 [Mazo GE, Kibitov AO. Mechanisms for the formation of comorbidity of depression and obesity. V.M. Bekhterev Review of Psychiatry and Medical Psychology. 2018;1:65-78 (In Russ.)].
  10. Fishta A, Backé EM. Psychosocial stress at work and cardiovascular diseases: an overview of systematic reviews. Int Arch Occup Environ Health. 2015;88(8):997-1014. doi: 10.1007/s00420-015-1019-0
  11. Li Z, Li Y, Chen P, Hu Y. Prevalence of Depression in Patients With Hypertension. Medicine (Baltimore). 2015;94(31):e1317. doi: 10.1097/md.0000000000001317
  12. Meng L, Chen D, Yang Y, et al. Depression increases the risk of hypertension incidence: A meta-analysis of prospective cohort studies. J Hypertens. 2012;30(5):842-51. doi: 10.1097/HJH.0b013e32835080b7
  13. Mannan M, Mamun A, Doi S, Clavarino A. Is there a bi-directional relationship between depression and obesity among adult men and women? Systematic review and bias-adjusted meta analysis. Asian J Psychiatr. 2016;21:51-66. doi: 10.1016/j.ajp.2015.12.008
  14. Васюк В.А., Довженко Т.В., Школьник Е.Л., Ющук Е.Н. Депрессивные и тревожные расстройства в кардиологии. М.: Анахарсис, 2009 [Vasyuk VA, Dovzhenko TV, Shkol’nik EL, Yushchuk EN. Depressive and Anxiety Disorders in Cardiology. Moscow: Anakharsis, 2009 (In Russ.)].
  15. Violan C, Foguet-Boreu Q, Flores-Mateo G, et al. Prevalence, determinants and patterns of multimorbidity in primary care: A systematic review of observational studies. PLoS One. 2014;9(7):e102149. doi: 10.1371/journal.pone.0102149
  16. Hiles SA, Révész D, Lamers F, et al. Bidirectional prospective associations of metabolic syndrome components with depression, anxiety, and antidepressant use. Depress Anxiety. 2016;33(8):754-64. doi: 10.1002/da.22512
  17. Meurs M, Groenewold NA, Roest AM, et al. The associations of depression and hypertension with brain volumes: Independent or interactive? NeuroImage Clin. 2015;8:79-86. doi: 10.1016/j.nicl.2015.03.020
  18. Ouakinin SRS, Barreira DP, Gois CJ. Depression and Obesity: Integrating the Role of Stress, Neuroendocrine Dysfunction and Inflammatory Pathways. Front Endocrinol (Lausanne). 2018;9:431. doi: 10.3389/fendo.2018.00431
  19. Lee S, Rhee DK. Effects of ginseng on stress-related depression, anxiety, and the hypothalamic–pituitary–adrenal axis. J Ginseng Res. 2017;41(4):589-94. doi: 10.1016/j.jgr.2017.01.010
  20. Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. Psychol Bull. 2014;140(3):774-815. doi: 10.1037/a0035302
  21. Toda N, Nakanishi-Toda M. How mental stress affects endothelial function. Pflugers Arch Eur J Physiol. 2011;462(6):779-94. doi: 10.1007/s00424-011-1022-6
  22. Mancia G, Grassi G. The autonomic nervous system and hypertension. Circ Res. 2014;114(11):1804-14. doi: 10.1161/CIRCRESAHA. 114.302524
  23. DeMarco VG, Aroor AR, Sowers JR. The pathophysiology of hypertension in patients with obesity. Nat Rev Endocrinol. 2014;10(6):364-76. doi: 10.1038/nrendo.2014.44
  24. Маянская С.Д., Попова А.А., Маянская Н.Н., и др. Артериальная гипертония и дисфункция эндотелия (Ч. II). Вестн. современной клинической медицины. 2009;2(3):43-8 [Mayanskaya SD, Popova AA, Mayanskaya NN, et al. Arterial hypertension and endothelial dysfunction (Part II). Vestn. sovremennoi klinicheskoi meditsiny. 2009;2(3):43-8 (In Russ.)].
  25. Grassi G, Seravalle G, Quarti-Trevano F. The “neuroadrenergic hypothesis” in hypertension: Current evidence. Exp Physiol. 2010;95(5):581-86. doi: 10.1113/expphysiol.2009.047381
  26. Izawa S, Saito K, Shirotsuki K, et al. Effects of prolonged stress on salivary cortisol and dehydroepiandrosterone: A study of a two-week teaching practice. Psychoneuroendocrinology. 2012;37(6):852-8. doi: 10.1016/j.psyneuen.2011.10.001
  27. Kim HS, Cho KI. Impact of chronic emotional stress on myocardial function in postmenopausal women and its relationship with endothelial dysfunction. Korean Circ J. 2013;43(5):295-302. doi: 10.4070/kcj.2013.43.5.295
  28. Leonard BE. The HPA and immune axes in stress: The involvement of the serotonergic system. Eur Psychiatry. 2005;20(Suppl. 3):302-6. doi: 10.1016/S0924-9338(05)80180-4
  29. Kyrou I, Chrousos GP, Tsigos C. Stress, visceral obesity, and metabolic complications. Ann N Y Acad Sci. 2006;1083:77-110. doi: 10.1196/annals.1367.008
  30. Kuo LE, Kitlinska JB, Tilan JU, et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med. 2007;13(7):803-11. doi: 10.1038/nm1611
  31. Nieuwenhuizen AG, Rutters F. The hypothalamic-pituitary-adrenal-axis in the regulation of energy balance. Physiol Behav. 2008;94(2):169-77. doi: 10.1016/j.physbeh.2007.12.011
  32. Aguilar-Valles A, Inoue W, Rummel C, Luheshi GN. Obesity, adipokines and neuroinflammation. Neuropharmacology. 2015;96(Part A):124-34. doi: 10.1016/j.neuropharm.2014.12.023
  33. Esser N, Legrand-Poels S, Piette J, et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(2):141-50. doi: 10.1016/j.diabres.2014.04.006
  34. Мазо Г.Э., Рукавишников Г.В. Патофизиологические механизмы формирования депрессии: фокус на лептин. Психическое здоровье. 2016;14(6):72-8 [Mazo G.E., Rukavishnikov G.V. Pathophysiological mechanisms of depression formation: focus on leptin. Mental health. 2016;14(6):72-8 (In Russ.)]
  35. Asferg C, Møgelvang R, Flyvbjerg A, et al. Leptin, not adiponectin, predicts hypertension in the copenhagen city heart study. Am J Hypertens. 2010;23(3):327-33. doi: 10.1038/ajh.2009.244
  36. Shankar A, Xiao J. Positive relationship between plasma leptin level and hypertension. Hypertension. 2010;56(4):623-8. doi: 10.1161/ HYPERTENSIONAHA.109.148213
  37. Guillemot-Legris O, Muccioli GG. Obesity-Induced Neuroinflammation: Beyond the Hypothalamus. Trends Neurosci. 2017;40(4):237-53. doi: 10.1016/j.tins.2017.02.005
  38. Jantaratnotai N, Mosikanon K, Lee Y, McIntyre RS. The interface of depression and obesity. Obes Res Clin Pract. 2017;11(1):1-10. doi: 10.1016/j.orcp.2016.07.003
  39. Schepers R, Markus CR. Gene×cognition interaction on stress-induced eating: Effect of rumination. Psychoneuroendocrinology. 2015;54:41-53. doi: 10.1016/j.psyneuen.2015.01.013
  40. Racette SB, Deusinger SS, Strube MJ, et al. Weight changes, exercise, and dietary patterns during freshman and sophomore years of college. J Am Coll Heal. 2005;53(6):245-51. doi: 10.3200/JACH.53.6.245-251
  41. Rivera M, Locke AE, Corre T, et al. Interaction between the FTO gene, body mass index and depression: Meta-analysis of 13701 individuals. Br J Psychiatry. 2017;211(2):70-6. doi: 10.1192/bjp.bp.116.183475
  42. Klenke S, Kussmann M, Siffert W. The GNB3 C825T polymorphism as a pharmacogenetic marker in the treatment of hypertension, obesity, and depression. Pharmacogenet Genomics. 2011;21(9):594. doi: 10.1097/FPC.0b013e3283491153
  43. Wenzel U, Turner JE, Krebs C, et al. Immune mechanisms in arterial hypertension. J Am Soc Nephrol. 2016;27(3):677-86. doi: 10.1681/ASN.2015050562
  44. Patel A. Review: The role of inflammation in depression. Psychiatr Danub. 2013;25(Suppl 2):216-23. doi: 10.1007/7854_2012_211
  45. Dowlati Y, Herrmann N, Swardfager W, et al. A Meta-Analysis of Cytokines in Major Depression. Biol Psychiatry. 2010;67(5):446-57. doi: 10.1016/j.biopsych.2009.09.033
  46. Rethorst CD, Bernstein I, Trivedi MH. Inflammation, obesity, and metabolic syndrome in depression: Analysis of the 2009-2010 National Health and Nutrition Examination Survey (NHANES). J Clin Psychiatry. 2014;75(12):1428-32. doi: 10.4088/JCP.14m09009
  47. Qin T, Liu W, Yin M, et al. Body mass index moderates the relationship between C-reactive protein and depressive symptoms: Evidence from the China Health and Retirement Longitudinal Study. Sci Rep. 2017;7(1):1-11. doi: 10.1038/srep39940
  48. Carpenter LL, Gawuga CE, Tyrka AR, Price LH. C-reactive protein, early life stress, and wellbeing in healthy adults. Acta Psychiatr Scand. 2012;126(6):402-10. doi: 10.1111/j.1600-0447.2012.01892.x
  49. Wium-Andersen MK, Ørsted DD, Nielsen SF, Nordestgaard BG. Elevated C-reactive protein levels, psychological distress, and depression in 73131 individuals. JAMA Psychiatry. 2013;70(2):176-84. doi: 10.1001/2013.jamapsychiatry.102
  50. Cheung BMY, Ong KL, Tso AWK, et al. C-reactive protein as a predictor of hypertension in the Hong Kong Cardiovascular Risk Factor Prevalence Study (CRISPS) cohort. J Hum Hypertens. 2012;26(2):108-16. doi: 10.1038/jhh.2010.125
  51. Cavalcanti AM, Kusma SZ, da Veiga Chomatas ER, et al. Noncommunicable diseases and their common risk factors in Curitiba, Brazil: results of a cross-sectional, population-based study. Rev Panam Salud Publica/Pan Am J Public Heal. 2018;(42):e57. doi: 10.26633/rpsp.2018.57
  52. Dumith SC, Maciel FV, Borchardt JL, et al. Health predictors and conditions associated to moderate and vigorous physical activity among adults and elderly from Southern Brazil. Rev Bras Epidemiol. 2019;22:e190023. doi: 10.1590/1980-549720190023
  53. Midei AJ, Matthews KA, Chang YF, Bromberger JT. Childhood physical abuse is associated with incident metabolic syndrome in mid-life women. Heal Psychol. 2013;32(2):121. doi: 10.1037/a0027891
  54. Pulkki-Råback L, Elovainio M, Kivimäki M, et al. Depressive Symptoms and the Metabolic Syndrome in Childhood and Adulthood: A Prospective Cohort Study. Heal Psychol. 2009;28(1):108-16. doi: 10.1037/a0012646
  55. Hare DL, Toukhsati SR, Johansson P, Jaarsma T. Depression and cardiovascular disease: A clinical review. Eur Heart J. 2014;35(21):1365-72. doi: 10.1093/eurheartj/eht462
  56. Dingemans A, Danner U, Parks M. Emotion regulation in binge eating disorder: A review. Nutrients. 2017;9(11):1274. doi: 10.3390/nu9111274
  57. Tomiyama AJ, Carr D, Granberg EM, et al. How and why weight stigma drives the obesity “epidemic” and harms health. BMC Med. 2018;16(1):123. doi: 10.1186/s12916-018-1116-5
  58. Moazzami K, Lima BB, Sullivan S, et al. Independent and Joint Association of Obesity and Metabolic Syndrome with Depression and Inflammation. Heal Psychol. 2019;38(7):586. doi: 10.1037/hea0000764
  59. Kiessling SG, McClanahan KK, Omar HA. Obesity, hypertension, and mental health evaluation in adolescents: A comprehensive approach. Int J Adolesc Med Health. 2008;20(1):5-15. doi: 10.1515/IJAMH.2008.20.1.5
  60. Недогода С.В., Барыкина И.Н., Чаляби Т.А., и др. Ожирение и артериальная гипертензия. Ч. II: особенности антигипертензивной терапии при ожирении. Кардиоваскулярная терапия и профилактика. 2009;8(1):88-98 [Nedogoda SV, Barykina IN, Chalyabi TA, et al. Obesity and hypertension. Part II: features of antihypertensive therapy in obesity. Kardiovaskulyarnaya terapiya i profilaktika. 2009;8(1):88-98 (In Russ.)].
  61. Захарова А.В., Лукина Ю.В., Воронина В.П., и др. Портрет больного ожирением по результатам амбулаторного регистра пациентов с сердечнососудистыми заболеваниями «Профиль». Кардиоваскулярная терапия и профилактика. 2016;15(4):44-9 [Zakharova AV, Lukina YuV, Voronina VP, et al. Portrait of a obesity patient by the results of the outlook register of patients with cardiovascular diseases “Profile”. Kardiovaskulyarnaya terapiya i profilaktika. 2016;15(4):44-9 (In Russ.)]. doi: 10.15829/1728-8800-2016-4-44-49
  62. Wofford MR, Anderson DC, Brown CA, et al. Antihypertensive effect of α- and β-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens. 2001;14(7):694-698. doi: 10.1016/S0895-7061(01)01293-6
  63. Firouzabadi N, Raeesi R, Zomorrodian K, et al. Beta adrenoceptor polymorphism and clinical response to sertraline in major depressive patients. J Pharm Pharm Sci. 2017;20:1-7. doi: 10.18433/j3w31f
  64. Salvi V, Mencacci C, Barone-Adesi F. H1-histamine receptor affinity predicts weight gain with antidepressants. Eur Neuropsychopharmacol. 2016;26(10):1637-77. doi: 10.1016/j.euroneuro.2016.08.012
  65. Licht CMM, Penninx BWJH, De Geus EJC. Effects of antidepressants, but not psychopathology, on cardiac sympathetic control: A longitudinal study. Neuropsychopharmacology. 2012;37(11):2487-95. doi: 10.1038/npp.2012.107
  66. Uher R, Mors O, Hauser J, et al. Changes in body weight during pharmacological treatment of depression. Int J Neuropsychopharmacol. 2011;14(3):367-75. doi: 10.1017/S1461145710000933

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies